BioCryst Pharmaceuticals (BCRX)
(Delayed Data from NSDQ)
$7.95 USD
-0.19 (-2.33%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $7.96 +0.01 (0.13%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth A Momentum C VGM
Fundamental Charts
About Market Cap
As of the previous market close, BioCryst Pharmaceuticals, Inc. has a market cap of $1.70B, which represents its share price of $8.14 multiplied by its outstanding shares number of 209.25M. As a small-cap company, BCRX's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
BCRX 7.95 -0.19(-2.33%)
Will BCRX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for BCRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BCRX
BioCryst Pharmaceuticals Before Q2 Earnings: How to Play the Stock
Analysts Estimate Esperion Therapeutics (ESPR) to Report a Decline in Earnings: What to Look Out for
BCRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
BioCryst Pharmaceuticals (BCRX) Reports Next Week: Wall Street Expects Earnings Growth
Is BioCryst Pharmaceuticals (BCRX) Outperforming Other Medical Stocks This Year?
Ensign Group Boosts U.S. Presence With Idaho and Texas Facility Buyouts
Other News for BCRX
BioCryst Pharmaceuticals Q2 2025 Earnings Preview
Earnings Outlook For BioCryst Pharma
BioCryst appoints Charlie Gayer to succeed Jon Stonehouse as CEO
BioCryst Pharmaceuticals Announces CEO Transition | BCRX stock news
BioCryst (BCRX) Announces Leadership Transition Plan